NCT05929859 Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders
| NCT ID | NCT05929859 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Syracuse University |
| Condition | Speech Sound Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2023-10-26 |
| Primary Completion | 2028-02-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 84 participants in total. It began in 2023-10-26 with a primary completion date of 2028-02-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized-controlled trial is to compare distributed treatment schedules and intensive treatment schedules in 84 school-age children with residual speech sound disorders. The main question it aims to answer is: * How does intensive and distributed treatment affect speech sound learning in residual speech sound disorder? Some participants will be treated with a traditional Distributed schedule of 2 sessions per weeks for 8 weeks (16 hours total), whereas others will be treated with an Intensive schedule and will complete 16 hours of treatment in 4 weeks.
Eligibility Criteria
Inclusion Criteria: * Must speak American English as a dominant language. * Must have began learning English by at least the age of 3 years. * Must be between 9;0 to 17;11 years of age. * Must have reported difficulty with /ɹ/ and/or /s/ production * Must pass pure tone hearing screening at 25 dB at 1000, 2000, and 4000 Hz. * Must receive a scaled score of at least 5 on the Listening Comprehension and Story Retelling subtests of the Test of Integrated Language and Literacy Skills (TILLS) * Must receive a percentile score of 5 or below on the Goldman-Fristoe Test of Articulation-3 (GFTA-3) Sounds in Words subtest. * Must have 1 scorable response with 5+ consecutive correct /pataka/ with \> 3.4 syllables per second in the MRR-Tri task of the Maximum Performance Tasks OR must demonstrate no childhood apraxia of speech (CAS-only) features in BOTH articulatory and rate/prosody domains of the ProCAD. * Must score \<40% accurate on /ɹ/ and/or /s/ probes assessing these sounds at the word level. * Must express a desire to modify their speech. Exclusion Criteria: * Must have no known history of autism spectrum disorder, Down Syndrome, cerebral palsy, intellectual disability, permanent hearing loss, or brain injury. * Must not have current cleft palate or voice disorder.
Contact & Investigator
Jonathan Preston, PhD
PRINCIPAL INVESTIGATOR
Syracuse University
Frequently Asked Questions
Who can join the NCT05929859 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, up to 17 Years, studying Speech Sound Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05929859 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05929859 currently recruiting?
Yes, NCT05929859 is actively recruiting participants. Contact the research team at jopresto@syr.edu for enrollment information.
Where is the NCT05929859 trial being conducted?
This trial is being conducted at Syracuse, United States.
Who is sponsoring the NCT05929859 clinical trial?
NCT05929859 is sponsored by Syracuse University. The principal investigator is Jonathan Preston, PhD at Syracuse University. The trial plans to enroll 84 participants.